Strides Pharma in Focus as Q4 Profit Surges 51%; Announces ₹5 Dividend for FY26 

Synopsis: Strides Pharma Science Ltd reported a strong Q4 FY26 performance with sharp growth in profitability supported by operational improvement and better business momentum across key markets. The pharmaceutical company also announced a final dividend of Rs. 5 per share for FY26. 

Strides Pharma Science Ltd is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products across regulated and emerging markets. The company has a strong presence in generic formulations and specialty pharmaceutical segments. India’s pharmaceutical sector continues to witness strong growth backed by rising healthcare demand, government support, and increasing exports, creating favorable opportunities for companies like Strides Pharma. 

Strides Pharma currently has a market capitalization of around Rs. 10,274 crore, with the stock trading near Rs. 1,151 down by 0.20% compared to its previous close of Rs. 1,153. The company has a stock P/E ratio of 18.7 and a book value of Rs. 299. The stock offers a dividend yield of 0.36%, while the company maintains ROCE of 14.7%. 

Strides Pharma reported revenue from operations of Rs. 1,323.47 crore in Q4 FY26, compared to Rs. 1,190.39 crore in the corresponding quarter last year, registering a growth of around 11 percent.  

Total income for the quarter stood at Rs. 1,331.60 crore, while total expenses increased to Rs. 1,178.59 crore due to higher employee costs, material expenses, and operational spending. Profit before exceptional items and tax rose sharply to Rs. 153 crore in Q4 FY26 compared to Rs. 130.67 crore in Q4 FY25, reflecting strong operational improvement. 

Profit before tax increased to Rs. 148.05 crore from Rs. 106.38 crore reported in the year-ago quarter. Profit after tax from continuing operations stood at Rs. 129.28 crore in Q4 FY26, registering a growth of nearly 51 percent compared to Rs. 85.62 crore reported in the corresponding quarter last year. 

The Board of Directors recommended a final dividend of Rs. 5 per equity share having a face value of Rs. 10 each for FY26. The company stated that the dividend will be paid within 30 days from the date of shareholder approval at the upcoming Annual General Meeting. 

Industry Outlook 

India’s pharmaceutical market stood at nearly Rs. 4.71 lakh crore in 2025 and is expected to grow to around Rs. 10.28–11.13 lakh crore by 2030. The sector continues to benefit from rising healthcare demand, export growth, and increasing global dependence on Indian pharmaceutical manufacturing. 

Government initiatives such as the Rs. 15,000 crore PLI scheme, API manufacturing push, and expanding Jan Aushadhi network are expected to support long-term industry growth. India also remains one of the world’s largest suppliers of low-cost medicines and vaccines, strengthening its position as a major global pharmaceutical hub. 

Strides Pharma delivered a strong Q4 FY26 performance with healthy growth in profitability and improving earnings per share. The company’s dividend announcement further reflects confidence in business stability and cash flow generation. With increasing global pharmaceutical demand, supportive government policies, and expanding healthcare opportunities, Strides Pharma remains well-positioned to benefit from long-term growth in the pharma sector.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies ontradebrains.inare their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Strides Pharma in Focus as Q4 Profit Surges 51%; Announces ₹5 Dividend for FY26  appeared first on Trade Brains.